The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Transthyretin Amyloidosis Treatment Market Over The Forecast Period?

The transthyretin amyloidosis treatment market has demonstrated strong growth in recent years. It is anticipated to increase from $4.96 billion in 2025 to $5.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. Historically, this expansion has stemmed from heightened recognition of hereditary amyloidosis, broader availability of genetic testing, the emergence of disease-modifying drugs, enhanced specialist referral networks, and a rise in rare disease registries.

The transthyretin amyloidosis treatment market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast timeframe is largely attributable to progress in next-generation attr therapies, increased investments in both pipeline and combination therapies, enhanced availability of specialty pharmacies, a growing need for tailored therapy selection, and sustained growth in clinical trial endeavors. Key trends expected within this period encompass the escalating creation of targeted attr therapies, increasing adoption of gene silencing medications, a heightened emphasis on managing multisystem diseases, an expansion of pipeline treatments for attr variants, and refined methods for patient stratification and ongoing monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

Which Growth Factors Are Strengthening The Transthyretin Amyloidosis Treatment Market Landscape?

Future expansion of the transthyretin amyloidosis treatment market is anticipated to be driven by increasing financial commitments to research and development (R&D). These R&D investments represent funding allocated to finding novel therapies, enhancing current treatments, and progressing scientific knowledge across various health conditions. The rise in R&D funding stems from a greater emphasis by both public and private entities on rare diseases, personalized medicine, and advanced therapeutic technologies. Increased capital in research and development speeds up the identification and progression of groundbreaking treatments, leading to better therapeutic choices and patient results for individuals with transthyretin amyloidosis. An example of this trend is seen in November 2023, where a report from the European Federation of Pharmaceutical Industries and Associations, a Belgium-based trade group, indicated that pharmaceutical industry R&D spending climbed to 50,000 million in 2023, an increase from 47,010 million in 2022. Consequently, the growing financial commitment to research and development is fueling the expansion of the transthyretin amyloidosis treatment market.

Which Segment Divisions Form The Structure Of The Transthyretin Amyloidosis Treatment Market?

The transthyretin amyloidosis treatment market covered in this report is segmented –

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs

3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN

2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

What Trends Are Influencing The Future Of The Transthyretin Amyloidosis Treatment Market?

Leading firms within the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are concentrating their efforts on creating novel therapies for ATTR-CM, including oral prescription drugs designed to target and stabilize transthyretin (TTR) proteins or mitigate amyloid fibril accumulation in the heart. Oral prescription medication encompasses drugs prescribed by medical professionals that are ingested orally, commonly as tablets, capsules, or liquid formulations. As an example, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration for Attruby (acoramidis) specifically for treating adults diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). This intervention works by stabilizing the TTR protein, thereby decreasing heart-related fatalities and the need for hospitalizations. Clinical trials have demonstrated its good tolerability and its capacity to deliver swift advantages by addressing the fundamental cause of the illness.

Who Are The Businesses Driving Activity In The Transthyretin Amyloidosis Treatment Market?

Major companies operating in the transthyretin amyloidosis treatment market are Pfizer Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals, Prothena Corporation plc, Eidos Therapeutics Inc, BridgeBio Pharma Inc, Neurimmune AG, AstraZeneca plc, Intellia Therapeutics Inc, Novo Nordisk A/S, YolTech Therapeutics Co Ltd, Life Molecular Imaging GmbH, Attralus Inc, Regeneron Pharmaceuticals, Silence Therapeutics, Proclara Biosciences, Corino Therapeutics, SOM Biotech, Oncopeptides AB, Takeda Pharmaceutical Company Limited, Horizon Therapeutics, Roche Holding AG, SOM Innovation Biotech SA

Access The Complete Transthyretin Amyloidosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Which Region Accounts For The Highest Share Of The Transthyretin Amyloidosis Treatment Market?

North America was the largest region in the transthyretin amyloidosis treatment market in 2025. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Transthyretin Amyloidosis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp

Browse Through More Reports Similar to the Global Transthyretin Amyloidosis Treatment Market 2026, By The Business Research Company

Atrophic Glossitis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report

Keloids Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Pigmentation Disorders Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pigmentation-disorders-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model